Evidence map›Paper›PMID 38424084›Full record

ArticleNature communications2024

Mesoporous nanoperforators as membranolytic agents via nano- and molecular-scale multi-patterning.

Yannan Yang, Shiwei Chen, Min Zhang, Yiru Shi, Jiangqi Luo, Yiming Huang, Zhengying Gu, Wenli Hu, Ye Zhang, Xiao He and 1 more

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Yannan Yang *Institute of Optoelectronics, Fudan University, Shanghai, 200433, China. yannan_yang@fudan.edu.cn.ORCID 0000-0001-6696-3879
Shiwei Chen *Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, Shanghai Frontiers Science Center of Molecule Intelligent Syntheses, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, 200241, China.
Min ZhangClinical Medicine Scientific and Technical Innovation Center, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, 200092, China. zgsydxzm@tongji.edu.cn.
Yiru ShiAustralian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, QLD, 4072, Australia.
Jiangqi LuoAustralian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, QLD, 4072, Australia.
Yiming HuangClinical Medicine Scientific and Technical Innovation Center, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, 200092, China.
Zhengying GuSchool of Chemistry and Molecular Engineering, East China Normal University, Shanghai, 200241, China.
Wenli HuSchool of Chemistry and Molecular Engineering, East China Normal University, Shanghai, 200241, China.
Ye ZhangSchool of Chemistry and Molecular Engineering, East China Normal University, Shanghai, 200241, China.
Xiao HeShanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, Shanghai Frontiers Science Center of Molecule Intelligent Syntheses, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, 200241, China. xiaohe@phy.ecnu.edu.cn.ORCID 0000-0002-4199-8175
Chengzhong YuAustralian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, QLD, 4072, Australia. c.yu@uq.edu.au.ORCID 0000-0003-3707-0785
East China Normal University · CNThe University of Queensland · AUTongji University · CNNew York University Shanghai · CN

Funding

National Natural Science Foundation of China (National Science Foundation of China) 21905093National Natural Science Foundation of China (National Science Foundation of China) 21922301National Natural Science Foundation of China (National Science Foundation of China) 22273023
6 · The paper itself

Abstract

Plasma membrane lysis is an effective anticancer strategy, which mostly relying on soluble molecular membranolytic agents. However, nanomaterial-based membranolytic agents has been largely unexplored. Herein, we introduce a mesoporous membranolytic nanoperforators (MLNPs) via a nano- and molecular-scale multi-patterning strategy, featuring a spiky surface topography (nanoscale patterning) and molecular-level periodicity in the spikes with a benzene-bridged organosilica composition (molecular-scale patterning), which cooperatively endow an intrinsic membranolytic activity. Computational modelling reveals a nanospike-mediated multivalent perforation behaviour, i.e., multiple spikes induce nonlinearly enlarged membrane pores compared to a single spike, and that benzene groups aligned parallelly to a phospholipid molecule show considerably higher binding energy than other alignments, underpinning the importance of molecular ordering in phospholipid extraction for membranolysis. Finally, the antitumour activity of MLNPs is demonstrated in female Balb/c mouse models. This work demonstrates assembly of organosilica based bioactive nanostructures, enabling new understandings on nano-/molecular patterns co-governed nano-bio interaction.

Indexed as

BenzeneNanostructuresAnimalsFemaleMicePhospholipidsBenzenePhospholipids

Identifiers

PMID38424084
PMCPMC10904871
OpenAlexW4392282801

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.